Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14921953 | 0.81 | PARP1 (0.55) | PARP1MAPTKDM4ELMNAGAA | |
| Hydrochloric Acid SCHEMBL7077252 | 0.80 | PARP1 (0.48) | PARP1 | |
| SCHEMBL5887737 | 0.77 | PARP1 (0.55) | PARP1MAPTKDM4EHTT | |
| SCHEMBL7083771 | 0.75 | PARP1 (0.52) | PARP1MAPTKDM4ERAB9AMEN1 | |
| SCHEMBL5887934 | 0.74 | PARP1 (0.48) | PARP1MAPTLMNA | |
| SCHEMBL7080676 | 0.71 | PARP1 (0.49) | PARP1 | |
| SCHEMBL20182558 | 0.70 | EPHX2 (0.41) | PARP1MAPTGAASMN1; SMN2NPSR1 | |
| SCHEMBL20182566 | 0.70 | EPHX2 (0.41) | PARP1MAPTGAASMN1; SMN2NPSR1 | |
| SCHEMBL6483613 | 0.69 | PARP1 (0.47) | PARP1MAPTGAAKMT2A | |
| SCHEMBL7081394 | 0.68 | PARP1 (0.43) | PARP1MAPTKDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6649618-B2 | Prevention and/or therapy of ischaemia and reperfusion damage; poly(ADP-ribose)-synthetase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2003-11-18 | — | — | US | disclosed |
| US-20030022905-A1 | Substituted amidoalkyl-uracils and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022905-A1 | Substituted amidoalkyl-uracils and their use | UNG, UMPS, TYMP | PARP1 283/4885MAPT 3594/4885KDM4E 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.